{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T18:21:01Z","timestamp":1778782861950,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin. Auton. Res."],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10286-025-01122-y","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T08:46:36Z","timestamp":1741423596000},"page":"347-352","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Carbidopa: beyond Parkinson\u2019s disease"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0725-636X","authenticated-orcid":false,"given":"Abhishek","family":"Lenka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Vernino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"key":"1122_CR1","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1001\/archneur.1974.00490380076010","volume":"31","author":"CH Markham","year":"1974","unstructured":"Markham CH, Diamond SG, Treciokas LJ (1974) Carbidopa in Parkinson disease and in nausea and vomiting of levodopa. Arch Neurol 31:128\u2013133. https:\/\/doi.org\/10.1001\/archneur.1974.00490380076010","journal-title":"Arch Neurol"},{"key":"1122_CR2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1017\/S0317167100020205","volume":"2","author":"DW Paty","year":"1975","unstructured":"Paty DW, Jaatoul N, Kertesz A, McInnis W (1975) Alpha methyldopahydrazine as an adjunct to levodopa therapy in Parkinson\u2019s disease. Can J Neurol Sci 2:169\u2013172. https:\/\/doi.org\/10.1017\/S0317167100020205","journal-title":"Can J Neurol Sci"},{"key":"1122_CR3","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1212\/wnl.25.10.911","volume":"25","author":"A Lieberman","year":"1975","unstructured":"Lieberman A, Goodgold A, Jonas S, Leibowitz M (1975) Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson\u2019s disease. Neurology 25:911\u2013916. https:\/\/doi.org\/10.1212\/wnl.25.10.911","journal-title":"Neurology"},{"key":"1122_CR4","doi-asserted-by":"publisher","first-page":"S497","DOI":"10.1002\/mds.22028","volume":"23","author":"S Fahn","year":"2008","unstructured":"Fahn S (2008) The history of dopamine and levodopa in the treatment of Parkinson\u2019s disease. Mov Disord 23:S497\u2013S508. https:\/\/doi.org\/10.1002\/mds.22028","journal-title":"Mov Disord"},{"key":"1122_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/mds.26082","volume":"30","author":"PA LeWitt","year":"2015","unstructured":"LeWitt PA (2015) Levodopa therapy for Parkinson\u2019s disease: pharmacokinetics and pharmacodynamics. Mov Disord 30:64\u201372. https:\/\/doi.org\/10.1002\/mds.26082","journal-title":"Mov Disord"},{"key":"1122_CR6","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1080\/14737175.2022.2091436","volume":"22","author":"A Lenka","year":"2022","unstructured":"Lenka A, Di Maria G, Lamotte G et al (2022) Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson\u2019s disease. Expert Rev Neurother 22:489\u2013498. https:\/\/doi.org\/10.1080\/14737175.2022.2091436","journal-title":"Expert Rev Neurother"},{"key":"1122_CR7","unstructured":"National Center for Biotechnology Information (2024) PubChem compound summary for CID 34359, Carbidopa. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Carbidopa. Accessed 20 Oct 2024"},{"key":"1122_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.07.003","volume":"203","author":"C Bucolo","year":"2019","unstructured":"Bucolo C, Leggio GM, Drago F, Salomone S (2019) Dopamine outside the brain: the eye, cardiovascular system and endocrine pancreas. Pharmacol Ther 203:107392. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.07.003","journal-title":"Pharmacol Ther"},{"key":"1122_CR9","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/apha.12229","volume":"211","author":"L-F Zheng","year":"2014","unstructured":"Zheng L-F, Song J, Fan R-F et al (2014) The role of the vagal pathway and gastric dopamine in the gastroparesis of rats after a 6-hydroxydopamine microinjection in the substantia nigra. Acta Physiol 211:434\u2013446. https:\/\/doi.org\/10.1111\/apha.12229","journal-title":"Acta Physiol"},{"key":"1122_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.13390","author":"C-Z Liu","year":"2018","unstructured":"Liu C-Z, Zhang X-L, Zhou L et al (2018) Rasagiline, an inhibitor of MAO-B, decreases colonic motility through elevating colonic dopamine content. Neurogastroenterol Motil. https:\/\/doi.org\/10.1111\/nmo.13390","journal-title":"Neurogastroenterol Motil"},{"key":"1122_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/j.1552-4604.1994.tb03980.x","volume":"34","author":"AB Alfieri","year":"1994","unstructured":"Alfieri AB, Cubeddu LX (1994) Effects of Inhibition of serotonin synthesis on 5-hydroxyindoleacetic acid excretion, in healthy subjects. J Clin Pharmacol 34:153\u2013157. https:\/\/doi.org\/10.1002\/j.1552-4604.1994.tb03980.x","journal-title":"J Clin Pharmacol"},{"key":"1122_CR12","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1017\/cjn.2017.284","volume":"45","author":"ACW Lau","year":"2018","unstructured":"Lau ACW, Diggle JL, Bring PP (2018) Improvement in severe orthostatic hypotension following carbidopa dose reduction. Can J Neurol Sci 45:252\u2013253. https:\/\/doi.org\/10.1017\/cjn.2017.284","journal-title":"Can J Neurol Sci"},{"key":"1122_CR13","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S0022-3565(25)28524-X","volume":"172","author":"VJ Lotti","year":"1970","unstructured":"Lotti VJ, Porter CC (1970) Potentiation and inhbition of some central actions of L(-)-dopa by decarboxylase inhibitors. J Pharmacol Exp Ther 172:406\u2013415","journal-title":"J Pharmacol Exp Ther"},{"key":"1122_CR14","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/mds.24998","volume":"27","author":"LS Brod","year":"2012","unstructured":"Brod LS, Aldred JL, Nutt JG (2012) Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson\u2019s disease. Mov Disord 27:750\u2013753. https:\/\/doi.org\/10.1002\/mds.24998","journal-title":"Mov Disord"},{"key":"1122_CR15","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10286-023-00941-1","volume":"33","author":"A Gonz\u00e1lez-Duarte","year":"2023","unstructured":"Gonz\u00e1lez-Duarte A, Cotrina-Vidal M, Kaufmann H, Norcliffe-Kaufmann L (2023) Familial dysautonomia. Clin Auton Res 33:269\u2013280. https:\/\/doi.org\/10.1007\/s10286-023-00941-1","journal-title":"Clin Auton Res"},{"key":"1122_CR16","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1086\/318810","volume":"68","author":"SA Slaugenhaupt","year":"2001","unstructured":"Slaugenhaupt SA, Blumenfeld A, Gill SP et al (2001) Tissue-specific expression of a splicing mutation in the gene causes familial dysautonomia. Am J Hum Genet 68:598\u2013605. https:\/\/doi.org\/10.1086\/318810","journal-title":"Am J Hum Genet"},{"key":"1122_CR17","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1212\/WNL.0b013e3181feb283","volume":"75","author":"L Norcliffe-Kaufmann","year":"2010","unstructured":"Norcliffe-Kaufmann L, Axelrod F, Kaufmann H (2010) Afferent baroreflex failure in familial dysautonomia. Neurology 75:1904\u20131911. https:\/\/doi.org\/10.1212\/WNL.0b013e3181feb283","journal-title":"Neurology"},{"key":"1122_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1750-1172-2-39","volume":"2","author":"FB Axelrod","year":"2007","unstructured":"Axelrod FB, Gold-von Simson G (2007) Hereditary sensory and autonomic neuropathies: types II, III, and IV. Orphanet J Rare Dis 2:39. https:\/\/doi.org\/10.1186\/1750-1172-2-39","journal-title":"Orphanet J Rare Dis"},{"key":"1122_CR19","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/MCG.0b013e3182582cbf","volume":"47","author":"LJ Norcliffe-Kaufmann","year":"2013","unstructured":"Norcliffe-Kaufmann LJ, Axelrod FB, Kaufmann H (2013) Cyclic vomiting associated with excessive dopamine in riley-day syndrome. J Clin Gastroenterol 47:136\u2013138. https:\/\/doi.org\/10.1097\/MCG.0b013e3182582cbf","journal-title":"J Clin Gastroenterol"},{"key":"1122_CR20","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1212\/WNL.0b013e31828f18f0","volume":"80","author":"L Norcliffe-Kaufmann","year":"2013","unstructured":"Norcliffe-Kaufmann L, Martinez J, Axelrod F, Kaufmann H (2013) Hyperdopaminergic crises in familial dysautonomia. Neurology 80:1611\u20131617. https:\/\/doi.org\/10.1212\/WNL.0b013e31828f18f0","journal-title":"Neurology"},{"key":"1122_CR21","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1161\/HYPERTENSIONAHA.120.15267","volume":"76","author":"L Norcliffe-Kaufmann","year":"2020","unstructured":"Norcliffe-Kaufmann L, Palma J-A, Martinez J, Kaufmann H (2020) Carbidopa for afferent baroreflex failure in familial dysautonomia: a double-blind randomized crossover clinical trial. Hypertension 76:724\u2013731. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15267","journal-title":"Hypertension"},{"key":"1122_CR22","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012149","author":"G Lamotte","year":"2021","unstructured":"Lamotte G, Coon EA, Suarez MD et al (2021) Natural history of afferent baroreflex failure in adults. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000012149","journal-title":"Neurology"},{"key":"1122_CR23","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1016\/j.jacc.2019.10.027","volume":"74","author":"I Biaggioni","year":"2019","unstructured":"Biaggioni I, Shibao CA, Diedrich A et al (2019) Blood pressure management in afferent baroreflex failure: JACC review topic of the week. J Am Coll Cardiol 74:2939\u20132947. https:\/\/doi.org\/10.1016\/j.jacc.2019.10.027","journal-title":"J Am Coll Cardiol"},{"key":"1122_CR24","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.jacc.2018.11.059","volume":"73","author":"M Bryarly","year":"2019","unstructured":"Bryarly M, Phillips LT, Fu Q et al (2019) Postural orthostatic tachycardia syndrome: JACC focus seminar. J Am Coll Cardiol 73:1207\u20131228. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.059","journal-title":"J Am Coll Cardiol"},{"key":"1122_CR25","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/01.CIR.53.5.749","volume":"53","author":"CF Wooley","year":"1976","unstructured":"Wooley CF (1976) Where are the diseases of yesteryear? DaCosta\u2019s syndrome, soldiers heart, the effort syndrome, neurocirculatory asthenia\u2013and the mitral valve prolapse syndrome. Circulation 53:749\u2013751. https:\/\/doi.org\/10.1161\/01.CIR.53.5.749","journal-title":"Circulation"},{"key":"1122_CR26","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.jacc.2020.12.029","volume":"77","author":"PR Taub","year":"2021","unstructured":"Taub PR, Zadourian A, Lo HC et al (2021) Randomized trial of ivabradine in patients with hyperadrenergic postural orthostatic tachycardia syndrome. J Am Coll Cardiol 77:861\u2013871. https:\/\/doi.org\/10.1016\/j.jacc.2020.12.029","journal-title":"J Am Coll Cardiol"},{"key":"1122_CR27","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1161\/CIRCULATIONAHA.108.846501","volume":"120","author":"SR Raj","year":"2009","unstructured":"Raj SR, Black BK, Biaggioni I et al (2009) Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more. Circulation 120:725\u2013734. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.846501","journal-title":"Circulation"},{"key":"1122_CR28","doi-asserted-by":"publisher","unstructured":"Okamoto LE, Urechie V, Rigo S et al (2024) Hyperadrenergic postural tachycardia syndrome: clinical biomarkers and response to guanfacine. Hypertension 81(11):2237-2247. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.124.23035","DOI":"10.1161\/HYPERTENSIONAHA.124.23035"},{"key":"1122_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.autneu.2021.102888","volume":"236","author":"EP Golden","year":"2021","unstructured":"Golden EP, Park CJ, Vernino S (2021) Symptomatic use of carbidopa in autonomic disorders. Auton Neurosci 236:102888. https:\/\/doi.org\/10.1016\/j.autneu.2021.102888","journal-title":"Auton Neurosci"},{"key":"1122_CR30","doi-asserted-by":"publisher","first-page":"540","DOI":"10.4049\/jimmunol.0903395","volume":"184","author":"KM Grebe","year":"2010","unstructured":"Grebe KM, Takeda K, Hickman HD et al (2010) Cutting edge: sympathetic nervous system increases proinflammatory cytokines and exacerbates influenza a virus pathogenesis. J Immunol 184:540\u2013544. https:\/\/doi.org\/10.4049\/jimmunol.0903395","journal-title":"J Immunol"},{"key":"1122_CR31","doi-asserted-by":"publisher","first-page":"7379","DOI":"10.1073\/pnas.1322174111","volume":"111","author":"M Kox","year":"2014","unstructured":"Kox M, van Eijk LT, Zwaag J et al (2014) Voluntary activation of the sympathetic nervous system and attenuation of the innate immune response in humans. Proc Natl Acad Sci USA 111:7379\u20137384. https:\/\/doi.org\/10.1073\/pnas.1322174111","journal-title":"Proc Natl Acad Sci USA"},{"key":"1122_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.637845","author":"F Brognara","year":"2021","unstructured":"Brognara F, Castania JA, Kanashiro A et al (2021) Physiological sympathetic activation reduces systemic inflammation: role of baroreflex and chemoreflex. Front Immunol 12:637845 https:\/\/doi.org\/10.3389\/fimmu.2021.637845","journal-title":"Front Immunol"},{"key":"1122_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104622","volume":"136","author":"NV Alen","year":"2022","unstructured":"Alen NV (2022) The cholinergic anti-inflammatory pathway in humans: state-of-the-art review and future directions. Neurosci Biobehav Rev 136:104622. https:\/\/doi.org\/10.1016\/j.neubiorev.2022.104622","journal-title":"Neurosci Biobehav Rev"},{"key":"1122_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100696","volume":"3","author":"MJ Kelly","year":"2022","unstructured":"Kelly MJ, Breathnach C, Tracey KJ, Donnelly SC (2022) Manipulation of the inflammatory reflex as a therapeutic strategy. Cell Rep Med 3:100696. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100696","journal-title":"Cell Rep Med"},{"key":"1122_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104293","volume":"146","author":"SK Elkhatib","year":"2019","unstructured":"Elkhatib SK, Case AJ (2019) Autonomic regulation of T-lymphocytes: Implications in cardiovascular disease. Pharmacol Res 146:104293. https:\/\/doi.org\/10.1016\/j.phrs.2019.104293","journal-title":"Pharmacol Res"},{"key":"1122_CR36","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2119\/2007-00105.Flierl","volume":"14","author":"MA Flierl","year":"2008","unstructured":"Flierl MA, Rittirsch D, Huber-Lang M et al (2008) Catecholamines\u2014crafty weapons in the inflammatory arsenal of immune\/inflammatory cells or opening Pandora\u2019s box? Mol Med 14:195\u2013204. https:\/\/doi.org\/10.2119\/2007-00105.Flierl","journal-title":"Mol Med"},{"key":"1122_CR37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/apha.12476","volume":"216","author":"M Levite","year":"2016","unstructured":"Levite M (2016) Dopamine and T cells: dopamine receptors and potent effects on T cells, dopamine production in T cells, and abnormalities in the dopaminergic system in T cells in autoimmune, neurological and psychiatric diseases. Acta Physiol 216:42\u201389. https:\/\/doi.org\/10.1111\/apha.12476","journal-title":"Acta Physiol"},{"key":"1122_CR38","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-018-0774-y","volume":"564","author":"V Staedtke","year":"2018","unstructured":"Staedtke V, Bai R-Y, Kim K et al (2018) Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature 564:273\u2013277. https:\/\/doi.org\/10.1038\/s41586-018-0774-y","journal-title":"Nature"},{"key":"1122_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183484","volume":"12","author":"H Zhu","year":"2017","unstructured":"Zhu H, Lemos H, Bhatt B et al (2017) Carbidopa, a drug in use for management of Parkinson disease inhibits T cell activation and autoimmunity. PLoS One 12:e0183484. https:\/\/doi.org\/10.1371\/journal.pone.0183484","journal-title":"PLoS One"},{"key":"1122_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/cplu.202400596","author":"AB Actis Dato","year":"2025","unstructured":"Actis Dato AB, Naso LG, Mart\u00ednez VR et al (2025) Carbidopa and ZnCarbidopa induce reductive stress in MDA-MB-231 cells. ChemPlusChem. https:\/\/doi.org\/10.1002\/cplu.202400596","journal-title":"ChemPlusChem"}],"container-title":["Clinical Autonomic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10286-025-01122-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10286-025-01122-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10286-025-01122-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T14:54:05Z","timestamp":1749048845000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10286-025-01122-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1122"],"URL":"https:\/\/doi.org\/10.1007\/s10286-025-01122-y","relation":{},"ISSN":["0959-9851","1619-1560"],"issn-type":[{"value":"0959-9851","type":"print"},{"value":"1619-1560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,8]]},"assertion":[{"value":"1 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}